The new leadership moves, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New leadership moves, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Leadership Trends
See who's moving and how much in your market
No credit card required Weekly executive digest
Alentis Therapeutics Appoints Dr. Alberto Toso As Chief Scientific Officer
PRIVATEApr 29, 2024•about 2 years ago
Company
Alentis Therapeutics
AllschwilManufacturing
Description
Dr. Alberto Toso has been appointed as Chief Scientific Officer at Alentis Therapeutics effective immediately. Alberto will be responsible for advancing and expanding the oncology pipeline, particularly targeting Claudin-1 for treating cancer.
Company Information
Company
Alentis Therapeutics
Location
Allschwil, Basel-Landschaft, Switzerland
About
Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1 (CLDN1) for oncology and multi-organ fibrosis. CLDN1 is a previously unexploited target that plays a key role in the pathology of cancer and fibrotic disease. Alentis is the leading company pioneering CLDN1 ADCs and antibodies to modify and reverse the course of select diseases.
AllschwilManufacturing